21st Jul 2017 15:30
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr N Hirons | ||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
| ||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 July 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction) | ||||
e) | Date of the transaction | 2017-07-20 | ||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr B McNamara | ||||
b) | Position/status | CEO, Consumer Healthcare | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| ||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 July 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-07-20 | ||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr D E Troy | ||||
b) | Position/status | SVP & General Counsel | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| ||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 July 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-07-20 | ||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||
Related Shares:
Glaxosmithkline